Kinnate Biopharma (NASDAQ:KNTE – Get Rating) announced its quarterly earnings results on Wednesday. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.02), Yahoo Finance reports.
Kinnate Biopharma Price Performance
NASDAQ:KNTE opened at $5.46 on Friday. Kinnate Biopharma has a one year low of $3.30 and a one year high of $15.86. The company has a fifty day moving average price of $6.19 and a 200 day moving average price of $8.24. The stock has a market cap of $241.17 million, a P/E ratio of -2.16 and a beta of 0.20.
Analyst Ratings Changes
Several research firms recently issued reports on KNTE. Wedbush decreased their price objective on shares of Kinnate Biopharma from $29.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday. Stifel Nicolaus decreased their price target on shares of Kinnate Biopharma from $11.00 to $8.00 and set a “hold” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Kinnate Biopharma currently has an average rating of “Moderate Buy” and an average target price of $25.00.
Institutional Investors Weigh In On Kinnate Biopharma
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- Dollar General Offers Great Prices, but the Stock isn’t a Value
- Jabil Inc.: Blue Chip Tech Stock Pulls Back To Buy Zone
- Should You Bring The Luck Of The Irish To Your Investmets?
- The Big Banks Join Forces to Save First Republic Bank
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.